In an analysis of the DISCOVER-2 trial, guselkumab treatment reduced impairment in work productivity and improved general health status in PsA over 2 years.
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with.